ARCA Biopharma, Inc.

Biopharmaceutical companies celebrated recent positive data readouts with a slew of significant follow-on public offerings (FOPOs), including Nuvalent, Inc. , which grossed $500m on 16 September from

Soon-to-be public Oruka Therapeutics will execute a reverse merger with ARCA Biopharma, Inc. and a concurrent $275m financing to help it start clinical development of optimized biologics in psoria

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer